{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:04:57Z","timestamp":1789362297856,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The systemic inflammatory response index (SIRI) has been confirmed to be associated with the prognosis of various solid tumors. The predictive value of the preoperative SIRI on the prognosis of bladder cancer (BC) patients remains unknown. This systematic review and meta-analysis investigated the association between preoperative SIRI and the prognosis of BC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant studies were retrieved from PubMed, Web of Science, Embase, the Cochrane Library, Chinese National Knowledge Infrastructure, Wan Fang database, and VIP Chinese Science and Technology Periodicals Database from inception to April 18, 2026. The prognostic value of preoperative SIRI for BC patients was assessed using pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Subgroup analyses were performed to investigate potential sources of heterogeneity, and sensitivity analyses were conducted to assess the robustness of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen studies comprising 4,098 patients were included. An elevated SIRI was significantly associated with poorer overall survival (OS; HR\u00a0=\u00a02.20, 95% CI\u00a0=\u00a01.61-3.01), recurrence-free survival (RFS; HR\u00a0=\u00a02.13, 95% CI\u00a0=\u00a01.74-2.61), and progression-free survival (PFS; HR\u00a0=\u00a04.06, 95% CI\u00a0=\u00a02.67-6.15) in BC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SIRI is a predictor of the survival, recurrence and disease progression in BC patients. Further large-scale prospective studies are required to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/inplasy.com\/inplasy-2026-5-0016\/<\/jats:ext-link>\n                      , identifier 202650016.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1876253","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:15Z","timestamp":1789360695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Dikai","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]},{"name":"The Second School of Clinical Medicine, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Guan","sequence":"additional","affiliation":[{"name":"Physical Examination Center, Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runmiao","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaguo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Affiliated Xiaoshan Hospital, Hangzhou Normal University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464635","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy: a systematic review and meta-analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1601040","article-title":"Prognostic value of lymphocyte to monocyte ratio for the patients with bladder cancer: a systematic review and meta-analysis","volume":"15","author":"Ren","year":"2025","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030380","article-title":"Prognostic significance of systemic immune-inflammation index in patients with bladder cancer: a systematic review and meta-analysis","volume":"101","author":"Cao","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1576845","article-title":"Prognostic value of systemic inflammation response index in patients with glioma: a meta-analysis","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2337729","article-title":"Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/20565623.2025.2526990","article-title":"Prognostic value of systemic inflammation response index in cervical cancer: a meta-analysis","volume":"11","author":"Zhang","year":"2025","journal-title":"Future Sci OA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1006233","article-title":"The prognostic predictive value of systemic immune index and systemic inflammatory response index in nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13643-025-02847-7","article-title":"Prognostic and clinicopathological impact of systemic inflammation response index (SIRI) on patients with esophageal cancer: a meta-analysis","volume":"14","author":"Wu","year":"2025","journal-title":"Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v16.i2.382","article-title":"Systemic inflammatory response index is a predictor of prognosis in gastric cancer patients: retrospective cohort and meta-analysis","volume":"16","author":"Ren","year":"2024","journal-title":"World J Gastrointest Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8441","DOI":"10.3390\/ijms25158441","article-title":"Inflammation and colorectal cancer: a meta-analysis of the prognostic significance of the systemic immune-inflammation index (SII) and the systemic inflammation response index (SIRI)","volume":"25","author":"Menyhart","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-087841","article-title":"Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis","volume":"14","author":"Ye","year":"2024","journal-title":"BMJ Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1291840","article-title":"Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1465279","article-title":"Prognostic role of systemic inflammation response index (SIRI) in patients with pancreatic cancer: a meta-analysis","volume":"14","author":"Shen","year":"2024","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1171-5","article-title":"The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis","volume":"22","author":"Tang","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/cancers17132189","article-title":"Prognostic value of PLR, SIRI, PIV, SII, and NLR in non-muscle invasive bladder cancer: can inflammatory factors influence pathogenesis and outcomes","volume":"17","author":"Bizzarri","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/medicina61101756","article-title":"AISI, SIRI, and MLR in predicting surgical outcomes after radical cystectomy: revisiting inflammatory risk markers","volume":"61","author":"Dama","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.01.007","article-title":"SIRI as a biomarker for bladder neoplasm: utilizing decision curve analysis to evaluate clinical net benefit","volume":"43","author":"Russo","year":"2025","journal-title":"Urol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x05282643","article-title":"The interpretation of random-effects meta-analysis in decision models","volume":"25","author":"Ades","year":"2005","journal-title":"Med Decis Making"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/curroncol32100534","article-title":"Pan-immune-inflammation value as a predictor of long-term outcomes in patients with urothelial carcinoma of the bladder: a pilot study","volume":"32","author":"Eren","year":"2025","journal-title":"Curr Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1644747","article-title":"Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study","volume":"15","author":"Feng","year":"2025","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1646723","article-title":"Prognostic risk factors and the role of systemic inflammatory response index in predicting outcomes for non-muscle-invasive bladder cancer","volume":"15","author":"Gui","year":"2025","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1005-6483.2023.07.019","article-title":"Predictive value of platelet lymphocyte ratio combined with systemic inflammatory response index for recurrence of non-muscle invasive bladder tumor after plasma resection","volume":"31","author":"Jianming","year":"2023","journal-title":"J Clin Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.12354\/j.issn.1000-8179.2023.20230616","article-title":"Impact of preoperative systemic inflammatory response index on the prognosis of intermediate-to-high-risk non-muscle invasive bladder cancer","volume":"50","author":"Jun","year":"2023","journal-title":"China J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.56434\/j.arch.esp.urol.20257806.89","article-title":"Value of preoperative inflammatory burden index in predicting overall survival and progression in nonmetastatic muscle-invasive bladder cancer","volume":"78","author":"Kayar","year":"2025","journal-title":"Arch Esp Urol"},{"key":"B32","volume-title":"A Predictive Model for Recurrence in Patients With non-Muscle- Invasive Bladder Cancer Based on Systemic Inflammatory Markers and Clinicopathological Features","author":"Ming","year":"2023"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.16766\/j.cnki.issn.1674-4152.003584","article-title":"Evaluation of prognosis in patients with high-grade non-muscle invasive bladder cancer using systemic inflammatory response index","volume":"22","author":"Nengyong","year":"2024","journal-title":"Chin J Gen Pract"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1009-8291.2021.06.010","article-title":"Prognostic value of systemic inflammation response index on aged patients with non-muscle-invasive bladder cancer","volume":"26","author":"Xin","year":"2021","journal-title":"J Modern Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5284","article-title":"Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer","volume":"12","author":"Ye","year":"2023","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.11.011","article-title":"The systemic inflammation response index: an independent predictive factor for survival outcomes of bladder cancer stronger than other inflammatory markers","volume":"41","author":"Yilmaz","year":"2023","journal-title":"Urol Oncol"},{"key":"B37","volume-title":"Prognostic Value of Systemic Inflammation and Tumor Immune Infiltration in Bladder Cancer and Construction of Prognostic Models","author":"Zhiqiang","year":"2024"},{"key":"B38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1541-7786.mcr-12-0274","article-title":"Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma","volume":"10","author":"van der Horst","year":"2012","journal-title":"Mol Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-2044","article-title":"Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2","volume":"66","author":"Chaffer","year":"2006","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2013.06.003","article-title":"Tumor associated macrophages and neutrophils in cancer","volume":"218","author":"Galdiero","year":"2013","journal-title":"Immunobiology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004651","article-title":"Neutrophils: between host defence, immune modulation, and tissue injury","volume":"11","author":"Kruger","year":"2015","journal-title":"PloS Pathog"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9594-9","article-title":"Neutrophils: important contributors to tumor progression and metastasis","volume":"34","author":"Swierczak","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-0006-x","article-title":"Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection","volume":"29","author":"Chen","year":"2012","journal-title":"Med Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12957-023-02943-9","article-title":"Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria","volume":"21","author":"Cinar","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33476","article-title":"Perioperative factors and 30-day major complications following radical cystectomy: A single-center study in Thailand","volume":"10","author":"Veerakulwatana","year":"2024","journal-title":"Heliyon"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:32Z","timestamp":1789360712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":55,"alternative-id":["10.3389\/fonc.2026.1876253"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876253","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1876253"}}